https://researchpepnews.com/articles/glp1-weight-maintenance-after-weight-loss Research Pep News en 2026-08-01 You Lost the Weight—Now What? The Unanswered Questions About GLP-1 Maintenance https://researchpepnews.com/images/editorial/glp1-weight-maintenance-strength-training.jpg A woman performs a squat on a plate-loaded machine while a trainer watches her form. Strength work can become part of a GLP-1 maintenance plan after weight loss. Photo by Gilson Gomes, published on Unsplash on April 20, 2026. https://researchpepnews.com/articles/tirzepatide-plateau-when-to-increase-dose Research Pep News en 2026-08-01 Stalled on Tirzepatide? What to Check Before Assuming You Need a Higher Dose https://researchpepnews.com/images/editorial/tirzepatide-plateau-scale-check.jpg A person stands barefoot on a digital bathroom scale. One reading cannot distinguish a change in body fat from short-term shifts in water or gut contents. Photo by i yunmai, published on Unsplash on April 4, 2018. https://researchpepnews.com/articles/glp1-insurance-denial-grey-market-options Research Pep News en 2026-08-01 Insurance Denied Your GLP-1—What Can You Actually Do Next? https://researchpepnews.com/images/editorial/glp1-insurance-denial-grey-market.png Many people are having to make difficult decisions about GLP-1 medications because of health-insurance coverage denials. Image: Research Pep News. https://researchpepnews.com/articles/peptides-vs-steroids-cjc1295-ipamorelin-sermorelin Research Pep News en 2026-08-01 Are Peptides Safer Than Steroids? The Case for CJC-1295, Ipamorelin and Sermorelin https://researchpepnews.com/images/editorial/peptides-vs-steroids-growth-hormone-lab.jpg A laboratory technician transfers liquid into a glass sample tube with a micropipette at a lab bench. The scene reflects the hormone and safety testing needed to compare endocrine drugs by evidence rather than marketing. Photo by Nathan Rimoux, published on Unsplash on May 26, 2025. https://researchpepnews.com/articles/tesamorelin-vs-cjc-1295-visceral-fat Research Pep News en 2026-08-01 Tesamorelin vs. CJC-1295 With and Without DAC: Could Different GH Patterns Produce the Same Visceral-Fat Effect? https://researchpepnews.com/images/editorial/tesamorelin-vs-cjc-1295-visceral-fat.png A medical illustration separates tesamorelin’s measured visceral-fat result from the two CJC-1295 hypotheses: sustained GH and IGF-1 exposure with DAC, and a short bedtime-aligned pulse without DAC. The comparison shows which findings come from human studies and which remain community hypotheses. Image: Research Pep News.